Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool.
While several blood tests for Alzheimer's diagnosis are in development, none are approved by regulators or insurance reimbursement.
Some are currently used to screen participants enrolling in Alzheimer's trials.
There is an ongoing debate about which blood biomarkers accurately signal the presence of amyloid and tau in the brain.
Currently, patients who could benefit from Eisai Co Ltd's (OTC: ESALY) / Biogen Inc's (NASDAQ: BIIB) new Alzheimer's drug, Leqembi, rely on cognitive assessments or invasive cerebrospinal fluid ...